Literature DB >> 20664900

Atherothrombosis and atrial fibrillation: Important and often overlapping clinical syndromes.

Jeremiah P Depta1, Deepak L Bhatt.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20664900     DOI： 10.1160/TH10-05-0332

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  16 in total

1.  Biomarkers: GDF-15 and risk stratification in atrial fibrillation.

Authors:  Francisco Marín; Vanessa Roldán
Journal:  Nat Rev Cardiol       Date:  2014-11-25       Impact factor: 32.419

2.  Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry.

Authors:  Jérémie Abtan; Deepak L Bhatt; Yedid Elbez; Emmanuel Sorbets; Kim Eagle; Yasuo Ikeda; David Wu; Mary E Hanson; Hakima Hannachi; Puneet K Singhal; Philippe Gabriel Steg; Gregory Ducrocq
Journal:  Clin Cardiol       Date:  2016-09-02       Impact factor: 2.882

3.  Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events.

Authors:  Gilles Lemesle; Gregory Ducrocq; Yedid Elbez; Eric Van Belle; Shinya Goto; Christopher P Cannon; Christophe Bauters; Deepak L Bhatt; Philippe Gabriel Steg
Journal:  Clin Cardiol       Date:  2017-07-10       Impact factor: 2.882

Review 4.  Peripheral artery disease and atrial fibrillation: a potentially dangerous combination.

Authors:  Francesco Violi; Gregory Y H Lip; Stefania Basili
Journal:  Intern Emerg Med       Date:  2011-06-11       Impact factor: 3.397

Review 5.  Impact of Atrial Fibrillation On Cardiovascular Mortality in the Setting of Myocardial Infarction.

Authors:  Mahmoud Suleiman; Doron Aranson
Journal:  J Atr Fibrillation       Date:  2012-12-16

6.  Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.

Authors:  Valentin Fuster; Deepak L Bhatt; Robert M Califf; Alan D Michelson; Marc S Sabatine; Dominick J Angiolillo; Eric R Bates; David J Cohen; Barry S Coller; Bruce Furie; Jean-Sebastien Hulot; Kenneth G Mann; Jessica L Mega; Kiran Musunuru; Christopher J O'Donnell; Matthew J Price; David J Schneider; Daniel I Simon; Jeffrey I Weitz; Marlene S Williams; W Keith Hoots; Yves D Rosenberg; Ahmed A K Hasan
Journal:  Circulation       Date:  2012-09-25       Impact factor: 29.690

Review 7.  Management of Anticoagulation in Patients with Atrial Fibrillation Undergoing PCI: Double or Triple Therapy?

Authors:  Benjamin E Peterson; Deepak L Bhatt
Journal:  Curr Cardiol Rep       Date:  2018-09-26       Impact factor: 2.931

8.  The Effects of Ranolazine on Paroxysmal Atrial Fibrillation in Patients with Coronary Artery Disease: A Preliminary Observational Study.

Authors:  Dionyssios Leftheriotis; Panayota Flevari; George Theodorakis; Angelos Rigopoulos; Ignatios Ikonomidis; Fotis Panou; Vassilios Sourides; Panagiotis Simitsis; Georgios Giannakakis; Isaac Aidonidis; Ioannis Rizos; Maria Anastasiou-Nana
Journal:  J Atr Fibrillation       Date:  2014-02-28

Review 9.  Managing Antiplatelet Therapy and Anticoagulants in Patients with Coronary Artery Disease and Atrial Fibrillation.

Authors:  Zubair Shah; Reza Masoomi; Peter Tadros
Journal:  J Atr Fibrillation       Date:  2015-12-31

Review 10.  Triple Therapy: When, if Ever?

Authors:  Nino Mihatov; Eric A Secemsky; Sammy Elmariah
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.